The most remarkable aspect of the US Food & Drug Administration’s approach to the review of pretomanid, a potential new treatment for highly resistant strains of tuberculosis submitted by the TB Alliance, is how routine it seemed.
Pretomanid has a Qualified Infectious Disease Product designation, signaling its special status in the context of the campaign to address microbial resistance. Like so many recent FDA approvals, the drug is focused on a significant unmet need in a small patient population, at least in the US where multi-drug resistant TB is extremely rare
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?